Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report-Reference-Cited by-同舟云学术

Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report

Published:2022-08 Issue:4 Volume:27 Page:135965352211199
ISSN:1359-6535
Container-title:Antiviral Therapy
language:en
Short-container-title:Antiviral Therapy

Author:

van der Veer Marlotte AA¹^ORCID,Jacobs Tom G²,Bukkems Laura H¹,Colbers Angela PH²,Burger David M²,Scherpbier Henriette J³,Bijleveld Yuma A¹

Affiliation:

1. Hospital Pharmacy, Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, The Netherlands

2. Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

3. Emma Children’s Hospital, Pediatric Infectious Diseases, Amsterdam University Medical Center, Amsterdam, The Netherlands

Abstract

We report a case of an infant with HIV receiving raltegravir granules for oral suspension and rifampicin-based TB prophylaxis. Raltegravir trough levels remained subtherapeutic and viral load increased during concurrent rifampicin therapy despite using double-dosed raltegravir. Even after rifampicin therapy, a higher dose was needed. This highlights the importance of therapeutic drug monitoring and dose adjustments of raltegravir in infants with rifampicin as comedication.

Publisher

SAGE Publications

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13596535221119932

Reference14 articles.

1. World Health Organization. Global tuberculosis report 2020, https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf

2. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review

3. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor

4. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age

5. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change;JAIDS Journal of Acquired Immune Deficiency Syndromes;2023-04-01

2. Antivirals/rifampicin;Reactions Weekly;2022-10-15